Intuitive Surgical, Inc. (ISRG) Covered Calls

Intuitive Surgical, Inc. covered calls Intuitive Surgical, Inc. is the global pioneer and leader in robotic-assisted, minimally invasive surgery. By 2026, the company has solidified its dominance through the full-scale global rollout of the da Vinci 5 system, which features 10,000 times the computing power of its predecessor. Under CEO David Rosa, Intuitive is expanding its reach into ambulatory surgery centers and specialized cardiac procedures, supported by its Ion endoluminal platform for lung biopsies.

You can sell covered calls on Intuitive Surgical, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ISRG (prices last updated Fri 3:45 PM ET):

Intuitive Surgical, Inc. (ISRG) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
485.11 +6.50 485.02 485.20 1.4M 61 170
Covered Calls For Intuitive Surgical, Inc. (ISRG)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 485 7.30 477.90 1.5% 68.4%
Mar 20 485 17.80 467.40 3.8% 38.5%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

Intuitive Surgical operates a highly profitable "razor-and-blade" business model, where a massive installed base of robotic systems drives recurring revenue through specialized instruments, accessories, and services. In 2026, recurring revenue accounts for over 80% of total sales. Their primary pillars include:

  1. da Vinci 5 System: The company's flagship fifth-generation platform, which introduced advanced force-feedback technology and AI-driven surgical insights. In early 2026, it received expanded FDA clearance for complex cardiac procedures.
  2. Ion Endoluminal System: A robotic-assisted platform for minimally invasive peripheral lung biopsies. In 2026, Ion is a major growth engine, benefiting from AI-powered "enhanced navigation" to improve diagnostic accuracy in lung cancer detection.
  3. Instruments and Accessories (I&A): A high-margin segment providing the specialized wristed tools used during robotic procedures. This remains the company's largest revenue stream, growing in tandem with global procedure volumes.
  4. Digital & AI Services: The "My Intuitive" platform and "Case Insights" software provide surgeons with performance data and video analytics, further embedding the company’s technology into hospital workflows.

Competitive Landscape

Intuitive maintains a dominant market share in robotic surgery but faces a growing field of challengers. Its primary rivals for large-scale multi-port systems are Medtronic and Johnson & Johnson, both of which are scaling their own robotic platforms in 2026. In the specialty and regional markets, it contends with Stryker for orthopedic applications and various local competitors in China. For diversified medical technology exposure, investors often compare ISRG to Boston Scientific and Edwards Lifesciences. Despite new entrants, Intuitive’s 20-year lead in clinical data and its installed base of over 11,000 systems provide a significant competitive moat.

Strategic Outlook and Innovation

The 2026 strategic roadmap for Intuitive is defined by "Intelligent Surgery and Site Expansion." After reporting record $10 billion revenue in 2025, the company is focusing 2026 efforts on the XIR Program—refurbished Xi systems tailored for the cost-sensitive U.S. ambulatory surgery center (ASC) market. Innovation is centered on Force-Feedback Instruments, which allow surgeons to "feel" tissue resistance through the robotic console, a first in the industry. A major 2026 milestone is the expected expansion of Japanese reimbursement for robotic procedures in June. Despite macro headwinds such as tariffs and Medicaid funding uncertainty, Intuitive maintains a "Great" financial health rating with $9 billion in cash and no debt. By integrating AI across the surgical workflow and expanding into new clinical indications like mitral valve repair, Intuitive aims to keep procedure growth in the mid-teens while maintaining its premium valuation in the healthcare sector.